NGM282 -- an engineered analogue of FGF19 -- shows promise in patients with primary sclerosing cholangitis

(European Association for the Study of the Liver) A Phase 2, randomized, double-blind, placebo-controlled study reports significant improvements in markers of disease activity and fibrosis with subcutaneous NGM282 in patients with primary sclerosing cholangitis.